| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Simeprevir |
| Brand | Olysio® |
| Indication | In combination with Sofosbuvir for the treatment of chronic hepatitis C (CHC) in adult patients who are intolerant to or ineligible for interferon therapy, and are in urgent need of treatment. |
| Assessment Process | |
| Rapid review commissioned | 27/05/2014 |
| Rapid review completed | 11/07/2014 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 30/10/2014 |
| Preliminary review sent to Applicant | 13/03/2015 |
| NCPE assessment outcome | Reimbursement recommended in some subgroups |
The NCPE recommends reimbursement of simeprevir in combination with sofosbuvir for genotype 1 in some subgroups
